Predictive Oncology (NASDAQ:POAI) Shares Pass Below 200 Day Moving Average of $2.29

Predictive Oncology Inc. (NASDAQ:POAI)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.29 and traded as low as $0.98. Predictive Oncology shares last traded at $1.01, with a volume of 37,978 shares traded.

Predictive Oncology Stock Performance

The stock has a market capitalization of $4.14 million, a P/E ratio of -0.28 and a beta of 1.15. The firm has a fifty day moving average price of $1.43 and a two-hundred day moving average price of $2.29.

Predictive Oncology (NASDAQ:POAI) last announced its earnings results on Tuesday, May 14th. The medical instruments supplier reported ($1.04) earnings per share (EPS) for the quarter. Predictive Oncology had a negative net margin of 754.13% and a negative return on equity of 151.51%. The business had revenue of $0.42 million for the quarter.

Institutional Investors Weigh In On Predictive Oncology

An institutional investor recently bought a new position in Predictive Oncology stock. Carnegie Mellon University acquired a new position in Predictive Oncology Inc. (NASDAQ:POAI) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology makes up approximately 0.0% of Carnegie Mellon University’s investment portfolio, making the stock its 5th largest holding. Carnegie Mellon University owned about 0.26% of Predictive Oncology as of its most recent filing with the Securities & Exchange Commission. 9.04% of the stock is owned by institutional investors.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.